Welcome to our dedicated page for Humana SEC filings (Ticker: HUM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Humana Inc. (NYSE: HUM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K, annual reports on Form 10-K and quarterly reports on Form 10-Q as they are filed with the U.S. Securities and Exchange Commission. As a major participant in Medicare Advantage, Medicaid managed care and related health insurance lines, Humana uses these filings to report financial results, guidance, leadership changes and other material events.
Recent Form 8-K filings for Humana include Regulation FD disclosures reaffirming earnings guidance and providing reconciliations between GAAP earnings per common share and Adjusted earnings per common share (Adjusted EPS), which management uses to analyze core operating performance and inform planning and incentive compensation. Other 8-Ks describe results of operations for specific quarters, preliminary Medicare Advantage Star Ratings information, and leadership transitions in the insurance segment, such as the planned retirement of an Insurance Segment President and the appointment of new leaders for Medicare Advantage and the broader insurance business.
Filings also reflect Humana’s role as a health insurer and managed care organization. AM Best’s rating actions, while separate from SEC filings, complement the picture provided in regulatory reports by describing the financial strength and business profile of Humana’s health and dental insurance subsidiaries, collectively known as Humana Health Group, and by noting the contribution of the CenterWell segment as a non-insurance source of revenue and earnings.
On Stock Titan, investors and researchers can use AI-powered summaries to quickly interpret lengthy documents such as 10-K and 10-Q reports, focusing on topics that matter for a company like Humana: Medicare Advantage and Medicaid performance, Star Ratings dynamics, non-GAAP metrics like Adjusted EPS, capital structure, and risk disclosures. The filings page also surfaces insider and executive-related disclosures reported on Form 8-K, helping users track leadership changes and compensation-related arrangements referenced in those reports. Real-time updates from EDGAR combined with AI explanations make it easier to follow how Humana communicates its financial condition, strategic initiatives and regulatory developments over time.
Humana Inc. director Raquel C. Bono reported equity awards and deferrals. The filing shows she acquired 766 restricted stock units as part of her annual director fee, which she elected to receive in stock units rather than cash. These units are deferred until she resigns from the board, at which time they will be settled in Humana common shares on a one-for-one basis under the company’s 2019 Amended & Restated Plan.
She also reported 34 additional stock units from dividend payments that were reinvested on already vested and deferred stock units. These dividend units are likewise deferred until she leaves board service and will then be paid in Humana common stock on a one-for-one basis.
Humana Inc. reported an insider equity transaction by its Chief Human Resources Officer, Michelle A. O'Hara. On 01/01/2026, she acquired 2,353 shares of Humana common stock through a transaction coded "M," at an exercise price of $0, reflecting the vesting or exercise of previously granted equity awards.
On the same date, she disposed of 1,093 shares, coded "F," at a price of $258.8675 per share, to cover tax liabilities related to shares vesting on that date, with no value received in return. After these transactions, she beneficially owned 9,541 shares of Humana common stock, which includes 7,512 restricted stock units that each represent a contingent right to receive one share under the company's 2019 Amended & Restated Plan.
Humana Inc. reported insider share transactions by its Chief Financial Officer, Celeste Mellet, dated 12/15/2025. She acquired 2,128 shares of Humana common stock at a price of $0, and 1,222 shares were disposed of at $270.155 per share to pay tax liabilities on vesting shares, with no value received in return.
Following these transactions, Mellet beneficially owned 28,454 Humana shares directly. This total includes 27,548 restricted stock units, each representing a contingent right to receive one share of Humana common stock under the Company's 2019 Amended & Restated Plan.
Humana Inc. Chief Information Officer Japan Mehta reported equity compensation activity in Humana common stock. On 12/15/2025, 1,194 shares were acquired at a reported price of $0, and 470 shares were disposed of at $270.155 to satisfy tax liability related to shares vesting on that date, with no value received in return.
After these transactions, Mehta beneficially owned 8,158 Humana shares directly. This total includes 7,434 restricted stock units that represent a contingent right to receive one share of Humana common stock each under the company’s 2019 Amended & Restated Plan. The report was signed on 12/17/2025.
Humana Inc. disclosed an insider stock transaction by its President, Enterprise Growth, David Dintenfass. On 12/15/2025 he exercised stock options for 2,032 shares of Humana common stock at an exercise price of $0 under the company’s 2019 Amended & Restated Stock Incentive Plan.
On the same date, 918 shares were disposed of at $270.155 per share to cover tax liabilities on vested restricted stock units, leaving 15,316 shares of common stock held directly, including 11,202 restricted stock units that each represent a right to receive one share. He also continues to hold stock options covering 51,389 shares at an exercise price of $367.21 per share, expiring on 02/21/2031 and vesting in three annual installments from 02/21/2025 through 02/21/2027.
Humana Inc. executive Sanjay K. Shetty, President of CenterWell, reported multiple equity award transactions dated 12/15/2025. He acquired 1,968 and 308 Humana common shares through equity awards at $0 per share, and disposed of 888 and 139 shares at $270.155 per share to satisfy tax liabilities on vesting, with no additional value received.
After these transactions, he directly beneficially owns 10,847 Humana common shares, which includes 8,818 restricted stock units that each represent a contingent right to one share. He also holds stock options covering 3,964 shares at an exercise price of $487.1602 expiring 04/01/2030 and 6,572 shares at $367.21 expiring 02/21/2031, all granted under Humana’s 2019 Amended & Restated Stock Incentive Plan.
Humana Inc. executive Michelle A. O'Hara reported routine equity compensation activity. On 12/15/2025, she acquired 1,401 shares of Humana common stock at $0 per share through a transaction coded "M". On the same date, 632 shares coded "F" were disposed of at $270.155 per share to cover tax liabilities on shares vesting that day, with no value received in return. After these transactions, she beneficially owned 10,634 shares, including 9,865 restricted stock units that each represent a contingent right to receive one share of Humana common stock under the company's 2019 Amended & Restated Plan.
Humana Inc.'s president and CEO James A. Rechtin reported equity transactions in company stock dated 12/15/2025.
He acquired 7,707 shares of Humana common stock at $0 per share through an option exercise, then disposed of 3,372 shares at $270.155 per share to satisfy tax liabilities for shares vesting on that date. After these transactions, he indirectly beneficially owned 27,102 shares, including 14,054 restricted stock units, held in revocable trusts for himself and his spouse.
He also holds stock options exercisable for 29,230 shares at $458.185 per share until 01/08/2031 and options for 15,772 shares at $367.21 per share until 02/21/2031, plus 4,366 additional restricted stock units.
Humana Inc. Chief Legal Officer Joseph C. Ventura reported several insider transactions in Humana common stock dated 12/15/2025. He acquired 2,046 shares and an additional 360 shares at an exercise price of $0 per share through stock option and restricted stock unit activity. To cover tax obligations on vesting shares, he disposed of 933 and 164 shares at $270.155 per share, with no value received in return.
After these transactions, Ventura beneficially owns 16,530 Humana common shares directly, including 6,250 restricted stock units, and 290 shares held indirectly in the Humana Retirement Savings Plan. He also holds stock options granted under Humana’s 2019 Amended & Restated Stock Incentive Plan covering 4,656, 4,598, 3,932, 4,162 and 6,572 shares, with exercise prices from $350.7875 to $510.2425 and expirations between 02/24/2027 and 02/21/2031.
Humana Inc. officer and President, Insurance, reported insider equity transactions dated 12/15/2025. He acquired 2,106 and 360 shares of Humana common stock at $0 per share through the vesting or exercise of equity awards, then disposed of 830 and 142 shares at $270.155 per share to pay tax liabilities on restricted stock vesting. After these transactions, he beneficially owned 15,459 shares directly and 525 shares indirectly through the Humana Retirement Savings Plan. His holdings also include 4,162 and 6,966 stock options, 9,059 restricted stock units representing contingent rights to receive common shares, and 172 phantom stock units linked to Humana common stock.
FAQ
What is the current stock price of Humana (HUM)?
What is the market cap of Humana (HUM)?
